Clinical laboratories under pressure as the Covid pandemic shuts down healthcare operations

0

DUBLIN, October 14, 2021 / PRNewswire / – The report “Global Clinical In Vitro Diagnostic Medical Laboratory Services, Q4 2021” has been added to ResearchAndMarkets.com offer.

The report includes detailed breakdowns for 15 countries and 4 regions. A detailed breakdown for any country in the world is available for buyers of the report.

The clinical lab has grown steadily over the past 20 years, but that is changing with the effect of the COVID pandemic on healthcare and economic activity. Worse yet, service points and self-testing threaten long-term demand. Understand the opportunities and threats in this comprehensive report.

The fundamentals are still there. Clinical laboratory tests are positioned to directly benefit from the explosion of biotechnology, particularly genomics. Learn all about it in this new report. A series of dynamic trends are driving market growth and company valuations.

Exciting technical developments, especially in the field of molecular diagnostics and pharmacogenomics, hold the promise of a dynamic, growing and evolving global market that is moving away from national and regional focus and heading into a stage global.

The report provides data that analysts and planners can use. Hundreds of pages of information, including a comprehensive list of current Medicare fee payment schedules in the United States for 2021, to help you refine your pricing. Make facility planning decisions. Forecast demand for new test regimes or technologies. Make research investment decisions.

Laboratory, Molecular diagnostics and genomic tests Recent developments

  • Thermo Fisher Obtains CE Mark for High Throughput COVID-19 Test
  • FDA issues alert – False negatives due to SARS-CoV-2 mutations
  • Will labs use extended molecular testing capabilities after COVID-19?
  • The cooperative aims to expand access to clinical and commercial NGS
  • Emerging COVID-19 Sequencing Trials – An Alternative to Existing Diagnostics?
  • CDC classifies two more microbes as “urgent threats”
  • ACLA requests $ 5 billion to operate private laboratories
  • Applied Biology to Launch New Lab for Hair and Skin Disorders
  • Quest Diagnostics acquires outreach operations
  • Quest Diagnostics Acquires Boston Clinical Laboratory Services Assets
  • CLA urges FDA to end crackdown on PGx tests
  • Quest Diagnostics Affiliate Acquires True Health Dx Assets
  • BioReference laboratories selected by the IPA Association
  • Predictive Laboratories announces research collaboration
  • NEOMED-LABS / Pacific Biomarkers acquires PAIRimmune Français
  • LabCorp and Envigo complete transactions
  • PathGroup acquires biomedical laboratories of pathologists
  • Predictive Technology acquires Taueret Laboratories
  • Quest Diagnostics Acquires Laboratory Services Business from Boyce & Bynum Pathology
  • Laboratories
  • Gestalt Diagnostics Expands Market Reach with Acquisition of Peak Medical
  • Amazon Explores Consumer Health Diagnostics
  • Quest Diagnostics Acquires Laboratory Services Operation at Central Michigan
  • NeoGenomics to acquire Genoptix, Inc
  • Quest Diagnostics to Acquire U.S. Laboratory Services Company of Oxford Immunotec
  • Charles River Laboratories to acquire a research company under contract to $ 800 million
  • GROUPE BIO7 sold to CERBA HEALTHCARE
  • GE Healthcare and Roche join forces to develop digital diagnostic platform

Trends driving a changing market

Growth is pushed from many sides

  • Understand the impact of the aging of the population.
  • Growth in COVID-related testing
  • Point-of-care testing can increase demand
  • Alternative medicine creates testing opportunity
  • Esoteric tests in movement for the general public
  • Genetic testing creates a new department and a new discipline

Factors at work to reduce the market

  • COVID 19 Recession
  • Economic or demographic contraction.
  • Test usage analytics to limit growth
  • Well-being has a downside
  • Testing displacement impacts Important
  • Point-of-service testing

Automating

  • LIMS investment failed
  • Software as a service
  • Doctor’s office and access systems

Environment and evolution

Development of diagnostic technology

  • Next Generation Sequencing Fuels a Revolution
  • Impact of NGS on pricing
  • Disruptive force POCT / self-test
  • Pharmacogenomics confuses diagnosis and treatment
  • CGES tests, a new and better world
  • Cutting-edge molecular diagnostic technologies
  • Giant biochip / magneto-resistance based assay

Key Company Profiles

  • Acibadem Labmed Laboratory
  • ACM Medical Laboratory
  • Adicon Clinical Laboratories
  • American bio-clinical laboratories, Int’l
  • American partners in pathology
  • ARUP Laboratories
  • Clinical Ascension
  • Aurora Diagnosis
  • Bio-Reference Laboratories
  • Bioscientia Institut fur Medizinische Diagnostik GmbH
  • BP Santé Group
  • Clinical reference laboratory
  • Clongen Laboratories
  • CompuNet Clinical Laboratories
  • America diagnostics
  • DIAN Diagnostics Co., Ltd
  • Enzo Life Sciences, Inc
  • Eurofins Scientific
  • Exagen Diagnosis
  • Genomic health
  • Genzyme Company
  • Gribbles Pathology
  • Guangzhou Kingmed Diagnostics Group Co., Ltd
  • Regional Integrated Laboratories
  • KDL Group
  • Laboratory Society of America
  • Lifelabs
  • Mayo Clinic Laboratories
  • Central American clinical laboratories
  • Myriad Genetics / Myriad RBM
  • NeoGenomics
  • Pathology, Inc.
  • Psychedelic Society
  • Quest Diagnosis
  • RDL Reference Laboratory
  • Sonic health care
  • Spectra Laboratories
  • Synlab Group
  • Unilabs

For more information on this report, visit https://www.researchandmarkets.com/r/zgr97x

Media contact:
Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com

Share.

Leave A Reply